Results 1 to 10 of about 14,557 (255)
Case Report: Exacerbation after fat grafting in patients with active localized scleroderma [PDF]
Frontiers in SurgeryBackgroundThe application of autologous fat transplantation in facial lesions of patients with localized scleroderma (LoS) has been reported in recent years.ObjectiveThe authors report a case of worsening of active localized scleroderma after autologous ...
Shunxin Han +3 more
doaj +3 more sources
Immunopathogenesis of Pediatric Localized Scleroderma [PDF]
Frontiers in Immunology, 2019 Localized scleroderma (LS) is a complex disease characterized by a mixture of inflammation and fibrosis of the skin that, especially in the pediatric population, also affects extracutaneous tissues ranging from muscle to the central nervous system ...
Kathryn S. Torok +11 more
doaj +5 more sources
Evaluation of Thiol Disulfide, Ischemia Modified Albumin, and Prolidase Parameters in Patients With Localized Scleroderma [PDF]
Dermatology Practical & ConceptualIntroduction: Localized scleroderma is a rare inflammatory skin disease that causes sclerosis in the dermis and subcutaneous tissue. Oxidative stress may play a role in the etiology or be responsible for the chronicity or progression of the disease ...
Ayşe Akbaş +5 more
doaj +3 more sources
Current Opinion in Rheumatology, 1989 Localized scleroderma has no recognized internal organ involvement. It may rarely coexist with a systemic connective tissue disease, but is not thought to progress to systemic sclerosis. Although never fatal, localized scleroderma may cause considerable disability from joint contractures and subcutaneous atrophy.
Vincent Falanga
+7 more sources
Localized scleroderma in children [PDF]
Przegląd Dermatologiczny, 2020 Localized scleroderma is an autoimmune disease affecting the dermis and underlying tissues (subcutaneous tissue, fascia, muscles, bones). The disease mainly occurs in women aged 20–50 years; however, children aged 7–10 years represent about 15% of all ...
Katarzyna A. Wolska-Gawron +1 more
doaj +2 more sources
Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review [PDF]
Pediatric Rheumatology Online JournalBackground Current treatment for localized scleroderma (LS) has been shown to halt disease activity, but little is still known about patient experiences with these treatments, nor is there consensus about optimal measurement strategies for future ...
Alexy Hernandez +5 more
doaj +2 more sources
Intramuscular Polydeoxyribonucleotides in Fibrotic and Atrophic Localized Scleroderma: An Explorative Prospective Cohort Study [PDF]
Biomedicines, 2023 Effective options in the quiescent, scantily inflammatory phase of localized scleroderma (morphea) are lacking. A cohort study in patients with histologically confirmed fibroatrophic morphea explored the therapeutic value of the anti-dystrophic A2A ...
Maurizio Romagnuolo +5 more
doaj +2 more sources
Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study
Acta Dermato-Venereologica, 2017 Recent findings indicate that patients with systemic sclerosis have an increased risk of cardiovascular disease. To determine whether patients with systemic sclerosis or localized scleroderma are at increased risk of cardiovascular disease, a cohort ...
Jeanette Halskou Hesselvig +5 more
doaj +3 more sources
Alʹmanah Kliničeskoj Mediciny, 2016 Background: Scleroderma is an autoimmune disease with progressing lesions of connective tissue where fibrosclerotic and vascular disturbances prevail.
O. A. Fomina +2 more
doaj +2 more sources
Successful treatment of localized scleroderma using brodalumab: A case report [PDF]
SAGE Open Medical Case ReportsWe report the first documented use of brodalumab, an IL-17 receptor antagonist, for treating severe linear localized scleroderma refractory to conventional therapies, including methotrexate, mycophenolate mofetil and corticosteroids.
Alexandra Carla Bobica +4 more
doaj +2 more sources